CA3293959A1 - Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases - Google Patents
Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseasesInfo
- Publication number
- CA3293959A1 CA3293959A1 CA3293959A CA3293959A CA3293959A1 CA 3293959 A1 CA3293959 A1 CA 3293959A1 CA 3293959 A CA3293959 A CA 3293959A CA 3293959 A CA3293959 A CA 3293959A CA 3293959 A1 CA3293959 A1 CA 3293959A1
- Authority
- CA
- Canada
- Prior art keywords
- rubidium
- neurodegenerative diseases
- zinc compounds
- treating parkinson
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3293959A CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3293959A CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| CA3154392A CA3154392A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| PCT/US2019/055770 WO2021071499A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154392A Division CA3154392A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3293959A1 true CA3293959A1 (en) | 2026-03-02 |
Family
ID=68387423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3293959A Pending CA3293959A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
| CA3154392A Pending CA3154392A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154392A Pending CA3154392A1 (en) | 2019-10-11 | 2019-10-11 | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11779597B2 (https=) |
| EP (1) | EP4041214A1 (https=) |
| JP (4) | JP7634895B2 (https=) |
| AU (1) | AU2019470001B2 (https=) |
| CA (2) | CA3293959A1 (https=) |
| WO (1) | WO2021071499A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2790926B2 (ja) * | 1990-08-20 | 1998-08-27 | エーザイ株式会社 | スルホンアミド誘導体 |
| DE69129611T2 (de) | 1990-08-20 | 1998-12-17 | Eisai Co., Ltd., Tokio/Tokyo | Sulfonamid-Derivate |
| US6162350A (en) | 1997-07-15 | 2000-12-19 | Exxon Research And Engineering Company | Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901) |
| WO2015185602A1 (en) | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
| US9861659B2 (en) | 2014-12-01 | 2018-01-09 | Vector Vitale Ip Llc | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| MX2018009662A (es) * | 2016-02-11 | 2018-09-11 | Chevion Mordechai | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. |
| CN106581056A (zh) * | 2016-10-11 | 2017-04-26 | 徐志强 | 锌在制造治疗帕金森病药物的用途 |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
-
2019
- 2019-10-11 CA CA3293959A patent/CA3293959A1/en active Pending
- 2019-10-11 EP EP19795409.2A patent/EP4041214A1/en active Pending
- 2019-10-11 JP JP2022522035A patent/JP7634895B2/ja active Active
- 2019-10-11 WO PCT/US2019/055770 patent/WO2021071499A1/en not_active Ceased
- 2019-10-11 US US17/768,190 patent/US11779597B2/en active Active
- 2019-10-11 AU AU2019470001A patent/AU2019470001B2/en active Active
- 2019-10-11 CA CA3154392A patent/CA3154392A1/en active Pending
-
2023
- 2023-08-28 US US18/238,817 patent/US12036238B2/en active Active
-
2024
- 2024-01-05 JP JP2024000684A patent/JP2024038270A/ja not_active Withdrawn
-
2025
- 2025-07-04 JP JP2025113738A patent/JP2025148408A/ja active Pending
- 2025-11-25 JP JP2025202951A patent/JP2026035686A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ787735A (en) | 2025-03-28 |
| JP2022551943A (ja) | 2022-12-14 |
| AU2019470001B2 (en) | 2024-09-19 |
| AU2019470001A1 (en) | 2022-05-12 |
| US11779597B2 (en) | 2023-10-10 |
| JP2026035686A (ja) | 2026-03-04 |
| CA3154392A1 (en) | 2021-04-15 |
| EP4041214A1 (en) | 2022-08-17 |
| JP7634895B2 (ja) | 2025-02-25 |
| JP2025148408A (ja) | 2025-10-07 |
| JP2024038270A (ja) | 2024-03-19 |
| US20230210894A1 (en) | 2023-07-06 |
| US20240173350A1 (en) | 2024-05-30 |
| WO2021071499A1 (en) | 2021-04-15 |
| US12036238B2 (en) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3297266A1 (en) | Compounds for the treatment of neurodegenerative and metabolic disorders | |
| EP3781564A4 (en) | Compounds for the treatment of cancer | |
| HK1252425A1 (zh) | 用於治疗脱髓鞘疾病的三唑类药物 | |
| EP3261446A4 (en) | Methods and compositions for the treatment or prevention of parkinson's disease | |
| PL3761982T3 (pl) | Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych | |
| EP3970710A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES BY ACTIVATION OF AUTOPHAGY | |
| CA3293959A1 (en) | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases | |
| EP3813872A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
| HK40071799A (en) | Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases | |
| EP3707507A4 (en) | METHOD OF PREDICTING THE TREATMENT OF PARKINSON'S MORBUS | |
| EP4010337A4 (en) | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR ASSOCIATED CLINICAL CONDITION | |
| PT3752173T (pt) | Combinação de rhodiola e de astragalus para o tratamento de doenças neurodegenerativas. | |
| HK40075186A (en) | Cuptsm for the treatment of neurodegenerative disorders | |
| HK40079762A (en) | Methods for treating parkinson's disease | |
| EP4072568A4 (en) | METHOD FOR TREATING PARKINSON'S DISEASE | |
| HK40061034A (en) | Compounds and compositions for the treatment of respiratory diseases | |
| HK40080038A (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| HK40064369A (en) | Compounds for the treatment of kinase-dependent disorders | |
| HK40073332A (en) | Methods for the treatment of epilepsy | |
| HK40067779A (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| HK40048106A (en) | Compositions and methods for the treatment of parkinson's disease | |
| HK40051477A (en) | Heterocyclic compounds for the treatment of epilepsy | |
| AU2018904242A0 (en) | Compounds and compositions for the treatment of respiratory diseases | |
| HK40076432A (en) | Compounds and methods for treating oxalate-related diseases | |
| HK40072482A (en) | Compounds for the treatment of kinase-dependent disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20251128 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251128 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20251231 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251231 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260128 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20260128 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20260302 |